Related Experiment Video
Updated: Jun 4, 2026

Isolation and Flow Cytometric Assessment of Neuroimmune Interactions in a Mini-Stroke Murine Model
Published on: June 20, 2025
microRNAs in stroke pathogenesis
1The Stroke Program, Departments of Biochemistry and Pharmacology, National University Health System, National University of Singapore, 8 Medical Drive, Singapore 117597.
Abstract:
Stroke is one of the leading causes of death and disability worldwide. There are two major types of stroke: cerebral ischemia caused by obstruction of blood vessels in the brain and haemorrhagic stroke that is triggered by the disruption of blood vessels. Thrombolytic therapy involving recombinant tissue plasminogen activator (rtPA) has been shown to be beneficial only when used within 4.5 hours of onset of acute ischemic stroke. rtPA treatment beyond this time window has been found to be unsuitable and usually resulting in haemorrhagic transformation. Stroke is a multifactorial disease that forms a possible end state for majority of patients suffering from diabetes, atherosclerosis and hypertension which are known risk factors. Although the biochemistry of stroke and related diseases is quite well understood, the knowledge on the molecular mechanisms underlying these diseases is still at its infancy. microRNAs that form a unique class of endogenous riboregulators of gene function, offer tremendous potential in unraveling the mechanisms underlying stroke pathogenesis. microRNA expression also reflects the response of individuals to drugs and therapy. Several microRNAs and their target genes, known to be involved in endothelial dysfunction, dysregulation of neurovascular integrity, edema formation, pro-apoptosis, inflammation and extra-cellular matrix remodeling contribute to the critical processes in the pathogenesis of stroke. In this review, we will also be discussing the role of microRNAs as possible diagnostic and prognostic biomarkers as well as potential therapeutic targets in stroke pathogenesis.
Insights
microRNAs offer new insights into stroke mechanisms and treatment. These small molecules show potential as diagnostic and therapeutic tools for stroke, a leading cause of death and disability.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Stroke is a major global cause of death and disability.
- Current treatments like rtPA have limited time windows.
- Molecular mechanisms of stroke pathogenesis are not fully understood.
Purpose of the Study:
- To explore the role of microRNAs in stroke pathogenesis.
- To discuss microRNAs as potential biomarkers and therapeutic targets for stroke.
Main Methods:
- Review of current literature on microRNAs and stroke.
- Analysis of microRNA involvement in key stroke processes.
Main Results:
- MicroRNAs are key regulators of gene function with potential in stroke research.
- Specific microRNAs and their targets are implicated in endothelial dysfunction, neurovascular integrity, edema, apoptosis, inflammation, and extracellular matrix remodeling.
- MicroRNA expression reflects individual responses to stroke therapies.
Conclusions:
- MicroRNAs are crucial in understanding stroke pathogenesis.
- MicroRNAs hold promise as diagnostic and prognostic biomarkers for stroke.
- MicroRNAs represent potential novel therapeutic targets for stroke treatment.
Related Concept Videos
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke ll: Pathophysiology
Ischemic Stroke l: Introduction
Hemorrhagic Stroke l: Introduction
Stroke: Introduction and Types